Rhythm wins Japan approval for Imcivree in acquired HO
Rhythm Pharmaceuticals says Japan's MHLW approves Imcivree (setmelanotide) for patients with acquired hypothalamic obesity, with launch in Japan expected by end of 2026 pending pricing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.